Coenzyme Q-10 and Pulmonary Arterial Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jacqueline Sharp, The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT01148836
First received: March 19, 2010
Last updated: March 19, 2015
Last verified: March 2015
  Purpose

The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension.


Condition Intervention
Pulmonary Arterial Hypertension
Dietary Supplement: Coenzyme Q-10 in Pulmonary Hypertension subjects
Dietary Supplement: Coenzyme Q-10 in Normal Control subjects

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension

Resource links provided by NLM:


Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Left Ventricular End Diastolic Volume [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
    Amount of blood in ventricle at end of diastole

  • Right Ventricular Outflow [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
    Velocity time interval

  • Right Ventricle Myocardial Performance [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
    Tei Index=(IRT+ICT)/ET, where IRT is isovolumic

  • Tricuspid Regurgitation Grade [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
    Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)

  • Right Atrial Pressure [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Red Blood Cells [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
  • Hemoglobin [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
  • Hematocrit [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
  • Mean Corpuscular Hemoglobin [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]
  • Red Blood Cell Distribution Width [ Time Frame: before and after three months of CoQ ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: January 2010
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Coenzyme Q 10 and Pulmonary Hypertension
PAH subjects to take Co-Q daily for three months
Dietary Supplement: Coenzyme Q-10 in Pulmonary Hypertension subjects
Take 100mg Co-Q for three times daily
Other Name: Coenzyme Q: Nutritional Supplement
Experimental: Coenzyme Q 10 and Normal Controls
Normal controls to take Co-Q daily for three months
Dietary Supplement: Coenzyme Q-10 in Normal Control subjects
Take 100mg Co-Q for three times daily

Detailed Description:

Abnormalities in the blood vessels in the lung are the hallmark of pulmonary hypertension. Links between increased free radical production, mitochondrial dysfunction and pulmonary hypertension have been studied but are poorly understood. The mitochondria of cells is the location where cellular energy is created and free radicals are atoms or groups of atoms with an odd (unpaired) number of electrons and can be formed when oxygen interacts with certain molecules. Once formed these reactive radicals can start a chain reaction, like dominoes. Their chief danger comes from the damage they can do when they react with important cellular components. Cells may function poorly or die if this occurs. The body produces free radicals in the normal course of energy production and in pulmonary hypertension, free radical production is found to be increased. To prevent free radical damage the body has a defense system of antioxidants. Coenzyme Q-10 is an antioxidant and it helps to protect cells from damage caused by the body's own free radicals. By providing oral supplementation of coenzyme Q-10, free radical levels will be decreased and cellular functioning in the pulmonary blood vessels may improve and even return to near normal functioning.

The purpose of this study is to evaluate the effects of coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension. We will assess coenzyme Q-10 supplementation in the treatment of pulmonary hypertension by clinical measurements and blood levels of certain cellular components. We would like to assess the effects of coenzyme Q-10 on the pulmonary vessels by measuring the lung diffusing capacity (a breathing test) and exhaled Nitric Oxide (NO) (a substance in the body that relaxes or dilates blood vessels). We will also measure endothelial progenitor cells (cells from the bone marrow) from a blood sample; these cells are markers of measure of blood vessel formation and repair. We will also measure the activity of superoxide dismutase (a protein in cells that executes the breakdown of a free radical into oxygen and hydrogen peroxide) in the blood. In addition, we will measure levels of coenzyme Q-10 in the blood. Other markers of disease response to therapy will be done including physical exam, BNP level (a blood marker that correlates with heart function), 6-minute walk and echocardiography (ultrasound of the heart). A total of 60ml (5 tablespoons) of blood will be drawn at each visit.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and Females age equal to or greater than 18 not to exceed 65.
  • Patients with PAH Class 1 (Venice 2003)
  • PAH medications must not have changed for the last two months.
  • Women of child-bearing age must use a double-barrier local contraception until completion of study.
  • Subjects must demonstrate understanding of study and sign informed consent and have a reliable method of communication for contact and the ability to comply with the study requirements.

Exclusion Criteria:

  • Participation in any other studies at the time of enrollment
  • History of any significant illness within four weeks of starting Coenzyme Q-10
  • Hepatic insufficiency (transaminase levels >4 fold the upper limit of normal or bilirubin >2 fold the upper limit of normal).
  • Renal insufficiency (creatinine >2)
  • Pregnancy,breast-feeding or lack of safe contraception.
  • Acute heart failure
  • Known allergy to the study drug or drugs similar to the study drug
  • History of drug or alcohol abuse within last 12 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01148836

Locations
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: Jackie Sharp, CNP The Cleveland Clinic
  More Information

No publications provided

Responsible Party: Jacqueline Sharp, Nurse Practitioner, The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT01148836     History of Changes
Other Study ID Numbers: 08-497
Study First Received: March 19, 2010
Results First Received: February 5, 2015
Last Updated: March 19, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:
Coenzyme Q-10
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Class I (Venice 2003)

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases
Coenzyme Q10
Ubiquinone
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins

ClinicalTrials.gov processed this record on April 30, 2015